Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ImClone Systems has announced that the cancer therapy evaluation program of the National Cancer Institute in the US has selected 10 proposals for Phase I/II clinical trials of its investigational cancer drug.
Subscribe to our email newsletter
The 10 selected trials represent the first stage of clinical evaluations of IMC-A12 NCI under a clinical trials agreement between ImClone Systems and the division of cancer treatment and diagnosis (DCTD), National Cancer Institute.
Both randomized and non-randomized Phase II trials will explore the clinical activity, pharmacology and biological effects of IMC-A12 as a single agent or combined with other relevant anticancer agents in a wide range of malignancies including breast, lung, pancreas and liver cancers, as well as both adult and pediatric sarcomas.
John Johnson, CEO, said: “This NCI program is a great opportunity for ImClone. These NCI-sponsored clinical trials will augment the broad disease-directed phase II program that ImClone has begun for IMC-A12. These studies will also expand our efforts with pediatric cancer patients at a relatively early juncture in IMC-A12's development.”